CureVac’s road to the coronavirus vaccine

German biopharmaceutical company CureVac is on track to launch a coronavirus vaccine based on an mRNA platform. Like its competitors, the company has brought many partners on board. But the large number of manufacturing and IP contracts pose a challenge for CureVac's growing legal and IP team.

20 April 2021 by Christina Schulze

CureVac, coronavirus vaccine Bayer and CureVac have agreed on an licencing contract to distribute the latter's coronavirus vaccine ©Tobias Arhelger/ADOBE STOCK

CureVac is currently developing a vaccine against the coronavirus, CV-nCoV. The biopharmaceutical company is expanding a broad integrated European production network, with experienced contract development and manufacturing organisation, in order to produce the vaccine. Marco Rau, general counsel at CureVac, says, “It gives us continued control over the process and closer involvement in production.”

CureVac, coronavirus vaccine

Marco Rau

He joined the Tübingen-based company two months ago from Merck in Darmstadt. So far, Rau’s team has included four other lawyers. The company’s legally-complex approach means it is planning for further growth.

CureVac is a key mRNA vaccine patent holder, along with Moderna, BioNTech and GSK. Before the Covid-19 pandemic, CureVac was known for its research into cancer vaccines. The basis of the development is a platform technology for vaccines.

Production facility under construction

CureVac will first launch the vaccine in Europe. Then, South America, Africa and Asia are among the planned markets.

Rau says, “CureVac has a very global vision, which we are also applying to the production of the coronavirus vaccine”. For example, CureVac has signed contracts with Wacker, Fareva, Novartis and other companies for the production of the vaccine.


Anita Buck

Furthermore, the company’s own production facility should be fully operational by the end of 2022. CureVac is partnering with major corporation Bayer, primarily for sales.

From Stuttgart, the CureVac legal and patent department is steering the implementation. Currently, the patent department comprises ten people, including four patent attorneys.

The company holds patents on mRNA platform technology and its further development. For many years on the IP side, Ulrich Kruse and Anita Buck – senior director IP licencing and senior director IP management, respectively – have managed the business.

Currently, JUVE Patent is not aware of the company’s involvement in any patent disputes.

Importance of co-operation

CureVac, coronavirus vaccine

Ulrich Kruse

The company frequently works with Graf von Stosch and Maiwald to file its patents.

In contract negotiations and regulatory matters, CureVac often hires a team from Baker & McKenzie led by Constanze Ulmer-Eilfort. Examples include a cooperation agreement with Bayer and a strategic agreement with GlaxoSmithKline. A few years ago, CureVac entered into a cooperation agreement with Boehringer Ingelheim for lung cancer immunotherapy.

CureVac also regularly works with a team led by Christian Lindemann from Voelker & Partner in Stuttgart in contract negotiations, including the agreement with Wacker.

Wacker negotiated the contract negotiations in-house, under the leadership of senior counsel Diana Massa. Karl-Heinz Rimböck, head of IP, handled the IP aspects, with the support of CBH partner Stephan Gruber.